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Chest pain is a common cause for attendance at emer­
gency and primary care consultation rooms. The life time 
prevalence accounts for 20 ­ 40% of the general population, 
with an incidence of 0.7% in primary care.[1] The majority 
of these presentations do not constitute a life­threatening 
illness, and the most common causes are musculoskeletal, respiratory, 
gastrointestinal and psychogenic. The challenge to the primary attending 
clinician is to rapidly and accurately diagnose potentially serious acute 
chest pain syndromes (Table 1), before turning attention to acute and 
chronic conditions that may also carry risk for mortality and morbidity, e.g. 
pneumonia, stable coronary artery disease (CAD), pericarditis, valvular 
heart disease, lung malignancies and abdominal pathologies. Finally, less 
serious conditions need consideration. At primary care level, clinicians 
need to identify serious conditions reliably while not exposing patients to 
unnecessary investigations and hospital admissions.[2] This review focuses 
on acute coronary syndromes (ACSs), which are the most common of the 
life­threatening chest pain presentations.
A clear stepwise approach to acute chest pain is critical to avoid mis­
diagnoses (Fig. 1). In the absence of chest trauma, the initial assessment 
should focus on ACS (acute myocardial infarction (MI) or unstable 
angina), aortic dissection, pulmonary embolism, cardiac tamponade, 
tension pneumothorax and, less commonly, acute abdominal syndromes 
presenting as chest pain. The patient’s history and risk factor profile, 
along with the clinical assessment, should direct the clinician to the next 
most appropriate diagnostic and therapeutic intervention. 
Emergency chest pain assessment
General considerations
Most chest pain algorithms aim to exclude ACSs. Initial and contin­
uous assessment of vital signs (blood pressure (BP), pulse, cardiac 
monitoring and oxygen saturations) should be standard care. If the 
patient is tachypnoeic or has oxygen saturations <94%, supplemental 
oxygen should be administered. Pain should be managed with 
appropriate analgesia, preferably intravenous opioids such as 
morphine. A focused history, thorough physical examination, meti­
culous review of a 12­lead electrocardiogram (ECG) and appro­
priately timed measurement of cardiac biomarkers are the key com­
ponents of an effective chest pain assessment. 
History 
The history is the most useful component when evaluating chest 
pain, as both normal and abnormal investigations (such as the ECG, 
cardiac biomarkers and chest radiograph (CXR)) must be interpreted 
in the context of the patient’s history. 
The mnemonic SOCRATES (Site Onset Character Radiation Asso­
ciation Time Exacerbating/relieving factor and Severity) helps differen­
tiate cardiac v. non­cardiac (respiratory, gastric or musculoskeletal) pain. 
Features that make a diagnosis of ACS likely include: central (retro­
sternal) location; sudden or acute onset; heavy or burning sensation with 
radiation to the arm or jaw; associated dyspnoea, nausea or sweating; 
duration >15 minutes; relief of symptoms by nitrates; worsening of 
symptoms by activity; chest or left­arm discomfort that is the same in 
nature as previously documented angina; and a known history of CAD 
(including prior MI).[3] Atypical presentations need to be considered in 
the elderly, diabetics and women.
At the primary care level, the Marburg Heart Score has been shown 
to have excellent negative predictive value (Table 2). Based only on 
variables acquired on history and examination, it is an easy­to­apply 
clinical prediction rule.[4]
Physical examination 
All patients presenting with acute chest pain should undergo a 
thorough physical examination. In ACS, the cardiac examination 
is often unremarkable, but specific attention should be paid to the 
vital signs (pulse and BP), features of heart failure, and auscultation 
precordial murmurs and rubs. The presence of transient mitral 
regurgitation, hypotension, diaphoresis, pulmonary oedema, crackles 
or signs of extracardiac vascular disease is highly suggestive of ACS. 
ACS is less likely if the presenting chest pain is reproducible by chest 
palpation.[3] Examination of the respiratory system should exclude 
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tension pneumothoraces and chest infections, while abdominal 
examination may reveal abdominal aetiologies.
12-lead ECG 
Patients presenting with acute chest pain should have a 12­lead ECG 
performed and interpreted within 10 minutes of first medical contact. 
If the initial ECG is non­diagnostic but the diagnosis of ACS is highly 
suspected, serial ECGs should be performed (at 3 hours, 6 hours, 
9 hours and 24 hours, or on recurrence of symptoms), including 
ECGs with additional leads for evaluation of the posterior­lateral 
myocardial wall V7 V8 V9 or V3R V4R V5R. ACS diagnostic features 
on the ECG include ST elevation, ST depression, T­wave inversion, and 
new or presumed new left bundle branch block. ECG features suggesting 
pericarditis include saddle­shaped ST elevation not confined to an 
anatomical location, with PR depression in V2 and PR elevation in aVR. 
ECG features suggestive of pulmonary embolism include tachycardia, 
features of right ventricular strain (T­wave inversion V1 ­ V3 with either 
right axis deviation or tall R in V1) and the typical SIQIIITIII pattern. 
Cardiac biomarkers 
Cardiac biomarkers reflect myocardial cell injury, the hallmark of 
MI. Pathophysiologically, MI results from ischaemia sufficient to 
cause cell death, with the release of cellular proteins and enzymes. 
Cardiac troponins I and T have been shown to be the most sensitive 
indicators of cardiac injury, as well as being predictors for short­ and 
long­term outcomes as regards death and MI.[5] The introduction of 
high­sensitivity troponin (hs­Tc) assays have improved rapid rule­
out MI, and the confirmation of non­ST elevation MI (NSTEMI).[6] 
It is important to understand that the increased sensitivity of the test 
results in lower specificity. To this end, the universal classification of 
MI was revised in 2012, acknowledging that for practical purposes, the 
diagnosis of ST elevation MI (STEMI) is made in the correct clinical 
setting with the appropriate ECG changes, and that MI without ST 
elevation (NSTEMI) requires positive biomarkers (Table 3). If serial 
biomarkers are negative, this implies no MI has occurred, but the 
patient may still require treatment for unstable angina. In addition, 
positive biomarkers may reflect myocardial injury secondary to non­
coronary causes – usually as a result of imbalance between myocardial 
oxygen supply and demand – and should therefore be interpreted in 
the clinical context of the presentation.[7] 
CXR
The CXR is helpful when pneumothorax or pneumonia, aortic 
dissection (wide mediastinum) or pulmonary embolism (oligaemia 
of lung fields or wedge­shaped infarcts) is suspected. If, on the 
Working diagnosis of ACS
Persistent ST
elevation
ST/T
abnormalities
Normal or
undetermined
ECG
Troponin
rise/fall
Troponin
normal
STEMI
Urgent REPERFUSION
Primary PCI or thrombolytic
therapy or pharmaco-invasive
therapy
NSTEMI Unstable angina
Anticoagulation, dual antiplatelet therapy,
risk stratication for invasive v.
conservative management
12-lead ECG diagnostic for ACS
Suspected ACS – cardiac biomarkers
(hs-Tc) for ACS with no ECG changes
12-lead ECG suggesting pericarditis –
diuse ST elevation, PR depression V2,
PR elevation aVR
Additional investigations guided by
clinical assessment and suspicion of
non-cardiac diagnosis:
CXR for infections (pneumonia),
pneumothorax, wide mediastinum for
dissection
CT for pulmonary embolism or aortic
dissection
Outpatient/non-emergent workup for
non-life-threatening diagnosis:
GI pathology – gastroscopy
Musculoskeletal pain
ACUTE CHEST PAIN
Assess vital signs
(BP, pulse, saturation, GCS,
respiratory rate)
Do 12-lead ECG (on presentation,
and repeat if ongoing chest pain or
recurrent chest pain, or at 3 hours)
Resuscitate
Likely aetiologies:
ACS (STEMI/NSTEMI)
pulmonary embolism; aortic
dissection; pericardial tamponade;
tension pneumothorax
Exclude life-threatening diagnoses:
ACS –12-lead ECG for ST-segment changes;
cardiac biomarkers (hs-Tc);
echocardiogram for wall motion
abnormalities
PE-CT pulmonary angiogram
Aortic dissection – CT angiogram,
echocardiogram
Pericardial eusion – echocardiogram or
ultrasound
No
Yes
Fig. 1. Chest pain algorithm (BP = blood pressure; GCS = Glasgow coma scale; ACS = acute coronary syndrome; hs-Tc = high-sensitivity troponin; 
GI = gastrointestinal; PCI = percutaneous coronary intervention; PE-CT = pulmonary embolism-computed tomography; STEMI = ST elevation myocardial 
infarction; NSTEMI = non-ST elevation myocardial infarction).
Table 1. Differential for acute chest pain
Cardiovascular 
Coronary artery disease 
Acute coronary syndromes 
Angina due to demand/supply mismatch 
Chronic stable angina 
Acutely increased myocardial oxygen demand 
Coronary vasospasm, ‘variant angina’
Cardiac syndrome X 
Coronary artery dissection 
Coronary anatomic anomalies 
Valvular heart disease 
Aortic dissection 
Pericarditis 
Myocarditis 
Stress­induced cardiomyopathy 
Acute aortic syndromes 
Chest pain related to hyperadrenergic states 
Cocaine intoxication 
Amphetamine intoxication 
Phaeochromocytoma 
Continued …
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basis of the ECG, ACS is suspected, the urgency of obtaining a 
CXR should be relegated and implementation of management plans 
prioritised. 
The management of ACSs
The clinical presentations of CAD include stable angina pectoris, 
silent ischaemia, unstable angina, MI, heart failure and sudden 
death.[8] ACSs result from acute destabilisation of coronary athe­
roma with resultant complete or subtotal thrombotic coronary 
occlusion. Ischaemic discomfort or chest pain is experienced 
because of reduction in blood flow to the myocardium. 
STEMI
Pathophysiology and initial diagnosis 
Plaque disruption exposes thrombogenic substances, resulting in 
intracoronary thrombus formation. Local anticoagulant production 
is increased and, if successful, will result in thrombus resolution and 
arrest of the infarction. However, if complete arterial occlusion occurs, 
myocardial ischaemia followed by infarction results, producing the 
typical ST elevation seen on the 12­lead ECG. Diagnostic patterns of 
ST elevation vary depending on which epicardial vessel is involved 
(Fig. 2).
Immediate management 
The optimal management of STEMI patients includes providing 
the fastest, safest, most effective method of reperfusion therapy 
available, i.e. primary percutaneous coronary intervention (PPCI) or 
fibrinolysis, while simultaneously initiating essential adjunct ther­
pies and monitoring (Fig. 3). Unless contraindicated, all patients 
should receive antiplatelet therapy (aspirin with P2Y12 inhibitors 
such as ticagrelor, prasugrel or clopidogrel) and anticoagulation 
(unfractionated or low­molecular­weight heparins (LMWHs) dosed 
to body weight). Patients should be connected to a cardiac monitor 
capable of cardioversion and transcutaneous pacing. Oxygen should 
be administered if the patient is hypoxic, and opioids for pain relief, 
breathlessness and anxiety are essential.[9]
Prehospital logistics of care 
The lack of a formal STEMI referral network for both public 
and private sectors makes decisions regarding reperfusion therapy 
challenging, and often impedes the rapid administration of 
reperfusion therapy.[10] Important timeframes that govern timely 
STEMI care are outlined in Fig. 4. Prehospital logistics and patient­
practitioner education should aim to reduce delays from time of 
symptom onset to definitive reperfusion.[9,11]
Reperfusion therapy 
This includes PPCI, fibrinolysis and pharmaco­invasive strategies. 
Selecting the most appro priate reperfusion strategy depends on three 
key factors: the time delay from symptom onset to first medical contact; 
availability; and clinical factors that may favour one strategy over the 
other.
Patients presenting within 12 hours of onset of symptoms (or 
since worse exacer bation) 
As a general guide, STEMI patients present ing to PCI­capable facilities 
should be offered PPCI (preferably within 60 min utes). If there is 
an anticipated delay of >120 minutes from the time of first medical 
contact, fibrinolysis should be administered. Patients presenting to 
Table 1. (continued) Differential for acute chest pain
Chest wall 
Isolated musculoskeletal chest pain syndromes 
Costochondritis 
Tietze syndrome 
Costovertebral joint dysfunction 
Sternalis syndrome 
Xiphoidalgia 
Spontaneous sternoclavicular subluxation 
Rheumatic diseases 
Non­rheumatic systemic diseases 
Stress fractures 
Metastatic malignancy 
ACS (sickle cell crisis) 
Skin and sensory syndromes 
Herpes zoster (shingles) 
Gastrointestinal 
Oesophageal 
Reflux 
Rupture 
Spasm 
Oesophagitis 
Pancreatobiliary 
Pancreatitis 
Cholecystitis 
Cholangitis 
Biliary colic 
Peptic ulcer disease 
Pulmonary 
Acute pulmonary embolism 
Pulmonary hypertension 
Pneumonia 
Cancer 
Sarcoidosis 
Asthma 
Chronic obstructive pulmonary disease 
Pleura 
Pleuritis 
Pneumothorax (including tension) 
Mediastinal disease 
Mediastinitis 
Mediastinal tumours 
Pneumomediastinum 
Psychiatric 
Anxiety 
Depression 
Panic attacks 
Munchausen syndrome
Table 2. The Marburg Heart Score
Criteria Score
Female >64 years; male >54 years 1
Known CAD, cerebrovascular disease or peripheral 
vascular disease
1
Pain worse with exercise 1
Pain not reproducible with palpation 1
Patient assumes pain is cardiac 1
Interpretation
~97% of patients with a score of ≤2 will not have CAD
~23% of patients with a score of >3 will have CAD
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non­PCI­capable facilities should be considered for fibrinolysis, or 
transfer for PPCI if PCI can be ensured within 120 min utes. It is 
important to remember that PPCI and fibrinolysis are of equivalent 
efficacy for patients presenting within 3 hours of symptoms, and every 
effort should be made not to delay reperfusion.[12] 
Fibrinolysis and pharmaco-invasive strategies 
In most sub­Saharan countries, access to PPCI­capable facilities is 
limited. Fibrino lysis is therefore the first choice reperfusion therapy. 
Clear contraindications to fibrino lysis need to be identified during the 
initial assessment (Table 4). Alteplase (tPA) with concomitant heparin 
was shown to be more effective than streptokinase (one fewer death 
per 100 patients treated, at the expense of three additional strokes). 
Tenectaplase is equivalent to accelerated tPA for 30­day mortality 
(with lower rate of bleeding).[13,14] Non­patient­related factors when 
considering choice of fibrinolysis include cost, ease of administration 
and administration in hospital or before being admitted.
Pharmaco­invasive management refers to the combination of 
fibrinolysis and angio graphy, with a view to PCI of the culprit lesion. 
Patients who have had successful fibrinolysis can be referred to a PCI­
capable centre for routine angiography and PCI within 24 hours of 
completing fibrinolysis. This strategy has been shown to reduce recurrent 
MI and urgent revascularisation for recurrent ACSs, and is currently a 
very attractive option in South African (SA) clinical settings.[15]
Patients presenting after 12 hours of symptom onset (or since 
worse exacerbation) 
Beyond 12 hours, fibrinolysis is far less effective than PPCI, while still 
carrying the risk of bleeding. Decisions regarding reperfusion should 
therefore be on an individual basis. Patients with persistent myocardial 
ischaemia, hypotension, haemodynamic instability or ventricular arrhyth­
mias should be considered for referral for angiography and PCI. Stable 
patients should receive antiplatelet therapy and anticoagulation with 
unfractionated heparins or LMWHs.[12]
Failed fibrinolysis
The 12­lead ECG should be repeated 60 (tPA) ­ 90 (streptokinase) 
minutes after fibrinolysis to assess therapeutic success. Failed fibrinolysis 
is indicated by failure of the ST elevation to reduce by >50% with or 
without persistent myocardial ischaemia. These patients do not benefit 
from repeat fibrinolysis, and should be considered for urgent rescue PCI, 
ideally within 12 hours.[12] 
NSTEMI and unstable angina  
Pathophysiology and initial diagnosis 
The pathophysiology of most NSTEMIs involves the rupture of a 
vulnerable athero matous plaque with subsequent throm bus forma­
tion, leading to reduced blood flow and ischaemia, with or without 
MI (NSTEMI or unstable angina (UA), respectively).
The diagnosis is confirmed by the presence of prolonged (>20 minutes) 
ischaemic chest pain, new­onset Canadian Class II or III angina, acute 
deterioration of stable chronic angina or angina following a recent MI, 
and the absence of ST elevation on the 12­lead ECG. Atypical complaints 
(including silent ischaemia, epigastric pain, indigestion and dyspnoea) 
can occur in older patients (>75 years), women and patients with 
diabetes, chronic kidney disease or dementia. In these settings, ST­T 
wave abnormalities on ECG should prompt rapid rule­out or rule­in 
of ACS using hs­Tc assays (Fig. 5).
Immediate management and risk stratification 
The immediate care of UA and NSTEMI patients involves two key 
steps: (i) risk stra tification using validated ischaemia and bleeding 
prediction tools before deciding on pharmacological and invasive 
management strategies; and (ii) the administration of evidence­based 
therapies. If there are no contraindications, a patient with a suspected 
diagnosis of ACS should receive antiplatelet therapy (aspirin and 
clopidogrel), anti coagu lation therapy (unfractionated heparins or 
LMWHs, or indirect factor Xa inhibitors (fondaparinux)), and 
anti­ischaemic agents (β­blockers, or calcium channel blockers and 
nitrates).
Validated ischaemic risk prediction scores (Thrombolysis in MI 
(TIMI) Risk Score and the Global Registry of Acute Coronary 
Events (GRACE) Risk Score) use demographic, clinical, ECG and 
biochemical variables to estimate the short­, intermediate­ and long­
term prognosis related to the current presentation (Table 5). The 
validated CRUSADE (Can Rapid risk stratification of Unstable angina 
patients Suppress ADverse outcomes with Early implementation of 
ACC/AHA guidelines)bleeding score combines eight predictors of 
major bleeding, allowing a physician to estimate the baseline risk of 
in­hospital major bleeding, therefore complementing ischaemic risk 
prediction tools. These scores are readily available as applications 
on smartphones and tablets, making them easy to use in daily 
practice. Patients with intermediate­ to high­risk scores should be 
considered for invasive management, and advanced for coronary 
angiography with a view to revascularisation. Independent of risk 
Table 3. Universal classification of MI (adapted from Thygesen et al.[7])
Type Description
Type 1: Spontaneous MI Related to atherosclerotic plaque rupture, ulceration, erosion or dissection with resultant coronary luminal 
thrombus in one or more coronaries, leading to decreased myocardial blood flow with ensuing myocyte necrosis. 
Patients may have underlying CAD (severe obstructive or mild non­obstructive) or no CAD.
Type 2: MI secondary to 
an ischaemic imbalance
Myocardial injury with necrosis secondary to an imbalance between myocardial oxygen supply and demand. Patients 
may or may not have underlying CAD. Common examples include coronary endothelial dysfunction, coronary artery 
spasm, tachycardias, bradycardias, anaemia, respiratory failure, hypotension and hypertension (with or without left 
ventricular hypertrophy).
Type 3: MI resulting in death 
when biomarker values are 
unavailable, or at autopsy
Cardiac death with symptoms and ECG changes of myocardial ischaemia or infarction, but death occurred before 
confirmatory biomarkers were obtained.
Types 4a and 4b: 
MI related to PCI
PCI­related infarction with elevation in cardiac troponins, symptoms of myocardial ischaemia, new ECG changes, 
angiographic changes (loss of vessel patency or new wall motion abnormality), or stent thrombosis.
Type 5: MI related to 
CABG
CABG­related infarction with elevation in cardiac troponins, symptoms of myocardial ischaemia, new ECG 
changes, angiographic changes (new graft or native coronary occlusion or new wall motion abnormality).
 PCI = percutaneous coronary interventions; CABG = coronary artery bypass grafting.  
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scores, patients with significant rise or fall of 
troponin levels, dynamic ECG changes and 
ongoing ischaemia should be considered for 
invasive management.
Timing of angiography and intervention 
High­risk patients benefit from revasculari­
sation therapy. Patients with ongoing ischae­
mia, acute heart failure, life­threatening 
ventricular arrhythmias or haemodynamic 
instability should be considered for immediate 
intervention regardless of biomarkers and 
ECG changes. Patients with high­risk scores 
who have clinically stabilised should be 
considered for angiography within 48 hours of 
admission. Low­risk patients may be managed 
medically, or have coronary angiography 
deferred. These timelines are a guide and 
may differ based on the availability of PCI­
capable centres. 
Hospitalisation and discharge 
All ACS patients should be managed in 
a high­care setting, specifically for the rapid 
identification and management of haemo­
dynamic (cardiogenic shock) and arrhyth­
mic (ventricular tachycardia and fibrillation) 
complications, as well as bleeding (access site 
or secondary to fibrinolysis) and recurrent 
infarction. ECG monitoring and bed rest should 
continue for at least 24 hours after successful 
reperfusion and symptom resolution. 
Chronic medications that offer mortality 
benefit should be introduced while in hospi­
tal (unless contraindicated). Dual anti plate let 
therapy should be continued for 1 year, unless 
there are specific reasons to stop sooner. The 
introduction of β­blockers, renin­angiotensin 
system inhibitors, angio tensin­converting 
enzyme inhibitors (ACE­Is), angiotensin 
receptor blockers (ARBs) or aldosterone 
antagonists) and statins should be specific 
to the individual, rather than introduced as 
a routine ‘cocktail’. The early introduction of 
high­dose HMG­CoA reductase inhibitors 
(statins) is also associated with improved 
survival and reduced morbidity. Beta­
blockers should be provided to all patients 
within 24 hours unless there is evidence of 
haemodynamic compromise, congestive heart 
failure or brady­arrhythmias (such as heart 
block). Patients with anterior MI, evidence 
of heart failure or depressed left ventricular 
systolic function should receive ACE­Is 
or ARBs, plus an aldosterone antagonist. 
Lifestyle and risk factor modification 
including smoking cessation, diet, physical 
activity and BP control is essential.[9] Patients 
who require surgical revascularisation should 
be discussed with a combined heart team 
(interventional cardiologist, clinical cardio­
logist and cardiothoracic surgeon) regarding 
the optimal timing of surgery (in­patient v. 
elective re­admission). 
ST elevation: New ST elevation at the J-point in two contiguous leads with the cut-points: 
≥0.1 mV in all leads other than leads V2 - V3 where the following cut-points apply: 
≥0.2 mV in men ≥40 years; ≥0.25 mV in men <40 years; ≥0.15 mV in women
Anterior STEMI: Typical ST elevation V2 - V5. 2A
Inferior STEMI: ST elevation in II, III, aVF. Also 
note the heart block.
2B
Lateral STEMI: ST elevation I and aVL, also V5 
and V6. ST depression noted II, III, aVF, V1, 
V2, V3.
2C
Posterior STEMI: Deep ST depression V1 - V3 
with prominent R waves V2, V3. When the 
ECG is viewed ‘from behind’, ST elevation in 
V1, V2, V3 is clearly seen.
2D and E
Left bundle branch block (new or presumed 
new) in the setting of ACS. Eponymous signs 
like Cabrera’s (notching in S-wave of V3 or 
V4) and Chapman’s (notching in R-wave 
of I, aVL, or V6) have poor sensitivity, but 
reasonable specificity. Using the Sgarbossa 
criteria may be helpful. 
2F
De Winter’s sign (proximal LAD occlusion): 
1 - 3 mm upsloping ST segment depression 
at the J-point in leads V1 - V6 that continue 
into tall, positive symmetrical T-waves. QRS 
complexes are not wide (<120 ms), and 
there may be loss of precordial R-wave 
progression. May have ST elevation (1 - 2 
mm) in aVR.[19]
2G
Atypical ECG presentations that deserve prompt management in patients with signs 
and symptoms of ongoing myocardial ischaemia include left bundle branch block, 
ventricular paced rhythms, isolated posterior MI, and ST elevation in lead aVR. 
Fig. 2. ST elevation MI variations.
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Less common ACS aetiologies
Infrequently, aetiologies other than ruptured atheroma result in 
ACS. Examples include coronary artery embolisation (in patients 
with atrial fibrillation, cardiomyopathy with ventricular clot or 
septic emboli from infective endocarditis), spontaneous coronary 
dissection (in patients with fibro muscular dysplasia, coronary 
vasculitis or thyrotoxicosis), coronary artery spasm (recreational 
drug use, de novo) and stress­induced cardiomyopathy (Takotsubo 
non­ischaemic cardiomyopathy). Careful history and clinical exam­
ination can often identify these patients prior to definitive ACS 
care. Even so, the general principles of management are as outlined 
above. 
ACSs in sub-Saharan Africa
ACSs are becoming increasingly prevalent in sub­Saharan Africa, 
with patients displaying similar myocardial risk factors to those of 
the developed world.[16,17] There are limited data regarding ACSs in 
the SA context, with observational data suggesting that there are high 
intervention rates and frequent use of evidence­based pharmacological 
therapies with comparative outcomes when compared with international 
standards.[18] These data reflect mainly the care delivered in the private 
sector, and do not fully represent care from the public sector where 
resources are limited and timely presentation to healthcare facilities 
capable of managing ACSs is often delayed.[10,16] Our current challenge 
is the provision of equal access and quality ACS care to all sectors of the 
SA population. This would entail reliance on the pharmaco­invasive 
strategy (routine and rescue) until there is adequate infrastructure 
expansion to accommodate the roll­out of a comprehensive, organised, 
hub­and­spoke PPCI service. Initiatives such as the European Society of 
Cardiology ‘Stent­for­Life’ project and planned national ACS registries 
could be the stepping stones to formalising management of ACSs on a 
national level. 
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therapy for STEMI patients.
Primary PCI-capable centre
Primary PCI
Rescue PCI
Routine pharmaco-invasive
coronary angiography and PCI
v. medical therapy
No
Immediate
transfer to
PCI centre
Yes
No
STEMI diagnosis
EMS of non-primary
PCI-capable  centre
PCI possible <120 minutes
Immediate
brinolysis
Successful brinolysis?
Immediate
transfer to
PCI centre
Yes
Fig. 4. Prehospital and inpatient management of STEMI (EMS = emergency 
medical services).
Acute chest pain
Treat as NSTEMI; risk stratify
for invasive management
Work-up for
dierential diagnosis
(consider chronic causes
of elevated troponin)
High-sensitivity troponin >ULN
No change
Repeat high-sensitivity troponin: 3 h
Signicant
change
(delta
troponin)
High-sensitivity troponin <ULN
Discharge or exercise
stress test
Pain free, GRACE <140,
dierential diagnosis excluded
No change
Pain < 6 hPain > 6 h
Ve
ry
 h
ig
h 
tr
op
on
in
 w
ith
cl
in
ic
al
 p
ic
tu
re
s 
of
 A
CS
Fig. 5. Rapid rule-out of ACS using high-sensitivity troponin (ULN = upper 
limit of normal).
Table 4. Contraindication to fibrinolysis
Absolute Relative
Previous intracranial 
haemorrhage or stroke of 
unknown origin at any time
Transient ischaemic attack in 
the preceding 6 months
Ischaemic stroke in the preceding 
6 months
Oral anticoagulation therapy
Central nervous system damage 
or neoplasm or atrioventricular 
malformations
Pregnancy or within 1 week 
post partum
Recent major trauma/surgery/
head injury (within preceding 
3 weeks)
Refractory hypertension 
(systolic BP >180 mmHg
and/or 
diastolic BP >110 mmHg)
Gastrointestinal bleeding within 
the past month
Advanced liver disease
Known bleeding disorder 
(excluding menses)
Infective endocarditis
Aortic dissection Acute peptic ulcer
Non­compressible puncture
in the past 24 hours (e.g. liver 
biopsy, lumbar puncture)
Prolonged or traumatic 
resuscitation
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Table 5. TIMI, GRACE and CRUSADE risk scores
TIMI risk score for UA/NSTEMI
Risk of cardiac events (%) by 14 days 
Variable Points Risk score Death or MI
Death, MI or urgent 
revascularisation
Age ≥65 years 1 0 ­ 1 3 5
≥3 CAD risk factors (family history, raised cholesterol, diabetes, 
hypertension)
1 2 3 8
Known CAD (stenosis ≥50%) 1 3 5 13
Aspirin use in past 7 days 1 4 7 20
Recent severe angina (last 24 hours) 1 5 12 26
Elevated cardiac biomarkers 1 6 ­ 7 19 41
ST deviation ≥0.5 mm 1
GRACE score for UA/NSTEMI
In-hospital mortality
Variables* Risk categories GRACE score Death, %
Age
Heart failure Low 1 ­ 108 <1
Peripheral vascular disease Intermediate 109 ­ 140 1 ­ 3
Admission systolic BP High 141 ­ 372 >3
Killip class 6 months post-discharge mortality
Elevated cardiac biomarkers Risk categories GRACE score Death, %
Initial serum creatinine Low 1 ­ 88 <3
Cardiac arrest on admission Intermediate 89 ­ 118 3 ­ 8
ST segment deviation High 119 ­ 263 >8
* Variables are inserted into an online calculator to generate the GRACE score 
(www.gracescore.org).
CRUSADE bleeding risk score
Variables† Risk categories CRUSADE score Bleeding risk, %
Baseline haematocrit Very low 1 ­ 20 3
Estimated glomerular filtration rate Low 21 ­ 30 5.5
Heart rate on admission Moderate 31 ­ 40 8.6
Systolic BP on admission High 41 ­ 50 12
Prior vascular disease Very high 51 ­ 90 20
Diabetes mellitus
Signs of congestive heart failure on admission
Gender
†Variables are inserted into an online calculator to generate the CRUSADE score (www.crusadebleedingscore.org/).
